NASDAQ:CKPTCheckpoint Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Checkpoint Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.20 +0.01 (+0.84 %) (As of 04/5/2020 02:41 PM ET) Add Compare Share Today's Range$1.18Now: $1.20▼$1.2350-Day Range$1.11MA: $1.73▼$2.4352-Week Range$1.05Now: $1.20▼$5.20Volume91,900 shsAverage Volume233,941 shsMarket Capitalization$66.05 millionP/E RatioN/ADividend YieldN/ABeta1.9 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the anti-PD-L1 antibodies anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCheckpoint Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.50, Checkpoint Therapeutics has a potential upside of 858.3% from its current price of $1.20.Amount of Analyst CoverageCheckpoint Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesCheckpoint Therapeutics has received 155 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCheckpoint Therapeutics has received 143 “underperform” votes. (Add your “underperform” vote.)Community SentimentCheckpoint Therapeutics has received 52.01% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Checkpoint Therapeutics and other stocks. Vote “Outperform” if you believe CKPT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CKPT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCheckpoint Therapeutics does not currently pay a dividend.Dividend GrowthCheckpoint Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Checkpoint Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.80% of the stock of Checkpoint Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 14.15% of the stock of Checkpoint Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Checkpoint Therapeutics are expected to grow by 16.39% in the coming year, from ($0.61) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Checkpoint Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Checkpoint Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCheckpoint Therapeutics has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CKPT Previous Symbol CUSIPN/A CIK1651407 Webhttp://www.checkpointtx.com/ Phone781-652-4500Debt Debt-to-Equity RatioN/A Current Ratio3.32 Quick Ratio3.32Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.71 million Price / Sales38.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book3.53Profitability EPS (Most Recent Fiscal Year)($0.70) Net Income$-24,710,000.00 Net Margins-1,446.95% Return on Equity-250.88% Return on Assets-138.15%Miscellaneous Employees7 Outstanding Shares55,040,000Market Cap$66.05 million Next Earnings Date5/14/2020 (Estimated) OptionableNot Optionable Receive CKPT News and Ratings via Email Sign-up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CKPT Rates by TradingView Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions How has Checkpoint Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Checkpoint Therapeutics' stock was trading at $1.33 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CKPT stock has decreased by 9.8% and is now trading at $1.20. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Checkpoint Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Checkpoint Therapeutics. When is Checkpoint Therapeutics' next earnings date? Checkpoint Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Checkpoint Therapeutics. How were Checkpoint Therapeutics' earnings last quarter? Checkpoint Therapeutics Inc (NASDAQ:CKPT) issued its quarterly earnings results on Wednesday, March, 11th. The company reported ($0.22) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.05. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.20 million. Checkpoint Therapeutics had a negative return on equity of 250.88% and a negative net margin of 1,446.95%. View Checkpoint Therapeutics' earnings history. What price target have analysts set for CKPT? 2 analysts have issued 12 month target prices for Checkpoint Therapeutics' stock. Their forecasts range from $8.00 to $15.00. On average, they expect Checkpoint Therapeutics' share price to reach $11.50 in the next year. This suggests a possible upside of 858.3% from the stock's current price. View analysts' price targets for Checkpoint Therapeutics. Has Checkpoint Therapeutics been receiving favorable news coverage? Headlines about CKPT stock have been trending very negative recently, according to InfoTrie. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Checkpoint Therapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutCheckpoint Therapeutics. Who are some of Checkpoint Therapeutics' key competitors? Some companies that are related to Checkpoint Therapeutics include Passage Bio (IMRA), Spectrum Pharmaceuticals (SPPI), Magenta Therapeutics (MGTA), Kamada (KMDA), Ocular Therapeutix (OCUL), Verrica Pharmaceuticals (VRCA), Syros Pharmaceuticals (SYRS), ProQR Therapeutics (PRQR), Evofem Biosciences (EVFM), Mersana Therapeutics (MRSN), Fulcrum Therapeutics (FULC), Rigel Pharmaceuticals (RIGL), Galera Therapeutics (GRTX), Gemphire Therapeutics (GEMP) and Albireo Pharma (ALBO). What other stocks do shareholders of Checkpoint Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include PTC Therapeutics (PTCT), TG Therapeutics (TGTX), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Avid Bioservices (CDMO), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE) and Verastem (VSTM). Who are Checkpoint Therapeutics' key executives? Checkpoint Therapeutics' management team includes the following people: Mr. James F. Oliviero III, CFA, CEO, Pres & Director (Age 43)Mr. William Garrett Gray, VP of Fin. & Accounting, Principal Financial Officer and Corp. Sec. (Age 32) What is Checkpoint Therapeutics' stock symbol? Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT." How do I buy shares of Checkpoint Therapeutics? Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Checkpoint Therapeutics' stock price today? One share of CKPT stock can currently be purchased for approximately $1.20. How big of a company is Checkpoint Therapeutics? Checkpoint Therapeutics has a market capitalization of $66.05 million and generates $1.71 million in revenue each year. The company earns $-24,710,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Checkpoint Therapeutics employs 7 workers across the globe. View additional information about Checkpoint Therapeutics. What is Checkpoint Therapeutics' official website? The official website for Checkpoint Therapeutics is http://www.checkpointtx.com/. How can I contact Checkpoint Therapeutics? Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected] This page was last updated on 4/5/2020 by MarketBeat.com StaffFeatured Article: What is the G-20?
